Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
SLN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.97 - $20.48
Previous CloseN/A
Volume50.54K
Average Volume (3M)91.86K
Market Cap
$291.41M
Enterprise Value-$3.30M
Total Cash (Recent Filing)$136.53M
Total Debt (Recent Filing)$60.00K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 14, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding47,230,280
10 Day Avg. Volume73,789
30 Day Avg. Volume91,859
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.01
Enterprise Value/Revenue-0.13
Enterprise Value/Gross Profit-0.17
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$37.50Price Target Upside530.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyDivesiran's final PhI update at EHA reinforces a differentiated profile in PV, including robust efficacy/safety and infrequent dosing, that could potentially drive a best-in-class opportunity.
Market OpportunityDespite PV's increasingly crowded landscape, PV remains a large commercial opportunity given high unmet need, evidenced by significant sales and partnerships.
Regulatory ProgressZerlasiran is advancing toward Phase 3 readiness in Lp(a), supported by regulatory alignment across the U.S., EU, and Japan, and active partnering discussions that management characterized as highly engaged.
Bears Say
Competitive LandscapeDespite PV's increasingly crowded landscape, PV remains a large commercial opportunity given the high unmet need and significant sales potential.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $1.97 and its highest was $20.48 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $291.41M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Aug 14, 2025 which is in 9 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on May 08, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.151 by -$0.049.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,230,280 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.151. Following the earnings report the stock price went down -3.784%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
Silence Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.50 (530.25% Upside)
$37.50 (530.25% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 364.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.82%
12-Months-Change
Fundamentals
Return on Equity
-99.23%
Trailing 12-Months
Asset Growth
-24.54%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
SLN Stock 12 Month Forecast
Average Price Target
$37.50
▲(530.25%Upside)
Technical Analysis
Regulus
―
Korro Bio
―
ADC Therapeutics
―
Kalaris Therapeutics
―
4D Molecular Therapeutics
―
Ownership Overview
28.25% Insiders
0.08% Mutual Funds
36.63% Other Institutional Investors
34.56% Public Companies and
Individual Investors